Aspen Group

Aspen Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Aspen Group (APZ.AX) as of Nov 13, 2026 is 59.45 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 37.47 % — a change of 58.66% (higher).

FCF Conversion

59.45 %

YoY

58.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Aspen Group is 2026 59.45 % . FCF Conversion Rate (FCF/EBITDA) of Aspen Group was 2025 37.47 % . It decreases by 58.66% higher compared to the previous year.

The Aspen Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
296.99 AUD
Jan 1, 2020
85.73 AUD
Jan 1, 2021
45.98 AUD
Jan 1, 2022
99.16 AUD
Jan 1, 2023
21.68 AUD
Jan 1, 2024
60.11 AUD
Jan 1, 2025
37.47 AUD
Jan 1, 2026
59.45 AUD
The Aspen Group FCF Conversion history
YEARFCF ConversionYoY
59.45 %+58.66%
37.47 %-37.66%
60.11 %+177.24%
21.68 %-78.13%
99.16 %+115.66%
45.98 %-46.37%
85.73 %-71.13%
296.99 %-108.20%
-3,622.42 %-17.42%
-4,386.55 %+2,090.29%
-200.27 %-194.25%
212.50 %-471.00%
-57.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aspen Group Stock analysis

What does Aspen Group do? Aspen Group Ltd is a globally active pharmaceutical company headquartered in Durban, South Africa. The company's history dates back to 1850, when the first pharmacy was opened by a man named William Charles in Durban. In 1997, Aspen Group Ltd was founded, which continued William Charles' business and expanded strongly in the following years. Aspen's business model is based on the acquisition of pharmaceutical companies and their products, as well as the production of generics and branded drugs. The company operates worldwide and has offices in over 50 countries. Aspen specializes in the fields of thrombosis, anesthesia, oncology, infectious diseases, and nervous system disorders. The various divisions of Aspen include Aspen Global Commercial, Aspen Pharmacare, Aspen Nutritionals, Aspen Oss, Aspen Business Europe, and Aspen Healthcare. Aspen Global Commercial is responsible for the sale of products in various regions of the world. Aspen Pharmacare is engaged in the production and sale of generics and branded drugs. Aspen Nutritionals produces dietary supplements and baby food. Aspen Oss manufactures and distributes bone substitute materials. Aspen Business Europe is responsible for product distribution in Europe, and Aspen Healthcare operates hospitals and health centers in South Africa. Aspen offers a variety of products, including anticoagulants, anesthetics, antibiotics, cancer drugs, HIV/AIDS medications, as well as dietary supplements and baby food. In the field of thrombosis, the company offers a wide range of anticoagulants, such as the active ingredients heparin, enoxaparin, and fondaparinux. In the field of oncology, Aspen produces drugs for the treatment of breast cancer, colon cancer, and lung cancer. Aspen's products are utilized by many different customers worldwide, including government agencies, hospitals, pharmacies, and retailers. Aspen places great emphasis on the quality of its products and has implemented a quality management system to ensure that the products meet the highest standards. In recent years, there have been controversies surrounding Aspen, particularly regarding drug pricing. In 2016, Aspen was fined €5.2 million by the European Commission for charging unreasonably high prices for cancer drugs in five European countries. Aspen has denied the allegations and announced plans to appeal the decision. Despite these controversies, Aspen remains an important player in the global pharmaceutical market. The company has a wide range of products and operates in various regions of the world. Aspen is committed to improving the health and well-being of people and continuously works to develop innovative and effective medications. Aspen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspen Group stock

FCF Conversion Rate (FCF/EBITDA) of Aspen Group is 59.45 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Aspen Group changed from 37.47 % to 59.45 %, representing a 58.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Aspen Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Aspen Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Aspen Group

All Key Metrics — Aspen Group